靶向加病灶周围活检在初诊前列腺MRI阳性患者中的非劣效随机对照试验
PERI-PRO非劣效随机对照试验纳入380例初诊、前列腺MRI单侧单发可疑病灶患者,比较靶向加病灶周围活检(TPLBx)与联合靶向加系统活检(CTSBx)。结果显示TPLBx在GG≥2和GG≥3前列腺癌检出率上非劣于CTSBx,且并发症更少、操作时间更短、病理成本更低。
要点
- TPLBx的GG≥2前列腺癌检出率非劣于CTSBx(58% vs 58%)。
- TPLBx并发症发生率显著低于CTSBx(62% vs 74%),出血相关并发症更少。
- TPLBx可缩短操作时间并节省病理成本(P < .001)。
核心结论
- 对于前列腺MRI单侧单发可疑病灶的初诊患者,TPLBx在临床显著前列腺癌诊断效能上非劣于CTSBx,且安全性更好。
研究设计与样本
- 单中心非劣效随机对照试验,连续纳入380例初诊患者(CTSBx组n=190,TPLBx组n=190),非劣效界值为-15%,所有活检经直肠认知融合技术进行。
主要发现
- TPLBx组与CTSBx组的GG≥2前列腺癌检出率均为58%(风险差RD:0.53%,95%CI:-9.4%至11%),GG≥3检出率均为30%(RD:0.53%,95%CI:-8.7%至9.7%),非劣效检验P < .001。
- 两组前列腺癌及GG1前列腺癌检出率无显著差异(P > .050)。
- TPLBx组并发症发生率显著低于CTSBx组(Clavien-Dindo≥1:62% vs 74%,P = .023),其中直肠出血(34% vs 48%,P = .003)、血尿(39% vs 56%,P < .001)和直肠疼痛(25% vs 34%,P = .018)均显著减少。
- TPLBx可显著缩短操作时间并节省病理成本(P < .001)。
关键数值与推荐
- 非劣效界值为-15%。
- 主要结局为GG≥2前列腺癌检出率:TPLBx组58% vs CTSBx组58%,RD:0.53%(95%CI:-9.4%至11%),P < .001。
- GG≥3前列腺癌检出率:30% vs 30%,RD:0.53%(95%CI:-8.7%至9.7%),P < .001。
- 并发症(Clavien-Dindo≥1):62% vs 74%,P = .023;直肠出血:34% vs 48%,P = .003;血尿:39% vs 56%,P < .001;直肠疼痛:25% vs 34%,P = .018。
临床怎么用
- 对于前列腺MRI显示单侧单发可疑病灶的初诊患者,可考虑采用TPLBx替代CTSBx,以在保证诊断效能的同时降低并发症、缩短操作时间并节约病理成本。
局限性
- 单中心研究,结论外推需谨慎。
- 所有活检均经直肠认知融合技术进行,结果可能不适用于其他穿刺途径或融合技术。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The combined targeted and systematic biopsy (CTSBx) was the standard scheme for patients with visible suspicious lesions on MRI in recent years. 2024 European Association of Urology guideline recommended targeted and perilesional biopsy (TPLBx) for the diagnosis of patients with MRI-visible suspicious lesions. This randomized controlled trial aims to comprehensively evaluate the efficacy and safety profiles of TPLBx and CTSBx schemes. MATERIALS AND METHODS: A single-center noninferiority randomized controlled trial consecutively enrolled 380 biopsy-naïve patients (CTSBx: n = 190, TPLBx: n = 190) with a single unilateral suspicious lesion on prostate MRI from June 2024 to November 2024. The noninferiority margin was -15%. All biopsies were undertaken transrectally through the cognitive fusion technique. The primary outcome was Grade Group (GG) ≥ 2 cancer (GG ≥ 2-PCa) detection rate. RESULTS: The GG ≥ 2-PCa (58% vs 58%, risk difference [RD]: 0.53% [95% CI: -9.4% to 11%]) and GG ≥ 3-PCa (30% vs 30%, RD: 0.53% [95% CI: -8.7% to 9.7%]) detection rates of TPLBx were noninferior to that of CTSBx (P < .001). There was no significant difference in PCa and GG1-PCa detection rates between the 2 groups (P > .050). The complication rate of TPLBx was significantly lower than that of CTSBx group (Clavien-Dindo scale ≥ 1: 62% vs 74%, P = .023), especially for bleeding-related complications (rectal bleeding: 34% vs 48%, P = .003; hematuria, 39% vs 56%, P < .001) and rectal pain (25% vs 34%, P = .018). TPLBx could significantly shorten the procedure time and saved the pathological cost (P < .001). CONCLUSIONS: For patients with a single unilateral suspicious lesion on prostate MRI, TPLBx achieved the noninferior diagnostic efficacy of clinically significant PCa and better safety than the CTSBx scheme. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT06482658.
引用
- Deng R, Li D, Wu J, et al. Comprehensive Evaluation of Targeted and Perilesional Biopsy in Biopsy-Naïve Patients With Prostate Positive Magnetic Resonance Imaging: PERI-PRO Noninferiority Randomized Controlled Trial. J Urol. 2025. PMID: 41270377. doi:10.1097/JU.0000000000004863
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。